RBC Capital Starts Climb Bio (CLYM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CLYM Hot Sheet
Price: $9.61 -1.44%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
RBC Capital initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Climb Bio click here. For more ratings news on Climb Bio click here.
Shares of Climb Bio closed at $11.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crude Inventory Fell 0.9 Million Barrels Last Week - EIA
- StoneX Reiterates Buy Rating on AMD (AMD)
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC Capital, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
